Drug profile · INN
zolpidem tartrate
ZOLPIDEM TARTRATE
zolpidem tartrate (ZOLPIDEM TARTRATE) is a gaba a receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. Associated with AYTU BIOPHARMA, INC. Route of administration: oral. Current US regulatory status: approved.
Drug details — zolpidem tartrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 0
- Data quality
- 0.89
Quick answer
zolpidem tartrate (ZOLPIDEM TARTRATE) is a gaba a receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. Associated with AYTU BIOPHARMA, INC. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
Primary target: GABA A receptor alpha-1/beta-1/gamma-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is zolpidem tartrate?
zolpidem tartrate (ZOLPIDEM TARTRATE) is a gaba a receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. Associated with AYTU BIOPHARMA, INC. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for zolpidem tartrate?
ZOLPIDEM TARTRATE is a marketed brand name for zolpidem tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zolpidem tartrate?
zolpidem tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.